Open Letter to Neurocrine: Please Make Chronocort (Efmody) Available to Adrenal Insufficiency Patients in the United States

To the Leadership Team at Neurocrine,

We respectfully ask that you make Chronocort (Efmody) available to patients living with adrenal insufficiency in the United States.

For many of us, this has been more than a medication under development—it has represented hope. We have been following its progress since 2016, eagerly anticipating the day it would become available in the U.S. Nearly a decade later, we are still waiting.

Patients and caregivers around the world have shared how Chronocort has transformed their lives. Families describe more stable cortisol coverage, fewer highs and lows throughout the day, improved quality of life, and the ability to live more normally. Parents report that their children have gone from being constantly sick to thriving.

For many families, the greatest burden is not simply taking medication—it’s the schedule.

Parents routinely stay awake until midnight or later to administer nighttime doses, then wake again before dawn to give the morning dose. This routine continues every day of the year. It affects sleep, careers, marriages, siblings, and the overall well-being of the entire household. Many families have lived with years of chronic sleep deprivation because maintaining proper cortisol replacement is literally lifesaving.

An extended-release option like Chronocort could dramatically reduce this burden by providing more physiologic cortisol replacement while requiring fewer daily doses. It has the potential to improve medication adherence, especially for teenagers and young adults, while helping patients maintain more stable cortisol levels throughout the day and night.

Patients in Europe have demonstrated what this therapy can accomplish. Although access remains limited in some countries because of reimbursement and commercialization challenges, those who have been able to receive Chronocort consistently describe it as life-changing.

We understand that bringing a medication to market involves significant regulatory, manufacturing, and commercial considerations. We appreciate the work that has already gone into developing this therapy. However, the adrenal insufficiency community in the United States has been waiting patiently for years, and we ask that this unmet need remain a priority.

We respectfully urge Neurocrine to prioritize making Chronocort available to adrenal insufficiency patients in the United States.

Our community has waited since 2016.

Sincerely,

Patients, Caregivers, Families, and Supporters of the Adrenal Insufficiency Community

Edit to add:

If Neurocrine doesn't plan to proceed with Chronocort, the AI community asks that Neurocrine may seek a potential buyer for the rights to the formulation so another company could pursue it instead.